Gujarat Themis Biosyn Q3 FY26 Results: Profit Rs 1246 Lakhs; Key Appointments Approved
Gujarat Themis Biosyn reported Q3 FY26 net profit of ₹1,246.46 lakhs. The board re-appointed Ms. Kirandeep Madan as Non-Executive Woman Independent Director for a five-year term starting May 1, 2026. Mr. Krupesh Patel will be the new CFO from April 1, 2026, succeeding Mr. Bhavik Shah who moves to a new role.
The re-appointment of an independent director and the appointment of a new CFO are significant for corporate governance and financial operations, but do not immediately impact the company's core business operations.
The company reported its financial results and approved key appointments, indicating stability and forward-looking management.
Gujarat Themis Biosyn Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company's board meeting commenced at 11:30 AM and concluded at 4:00 PM on February 5, 2026.
The board approved the unaudited financial results for the quarter and nine months ended December 31, 2025, along with the limited review report from M/s. GMJ & Co., Chartered Accountants.
Key personnel changes were also approved. Ms. Kirandeep Madan has been re-appointed as Non-Executive Woman Independent Director for a second term of five years, from May 1, 2026, to April 30, 2031, subject to shareholder approval. Additionally, Mr. Krupesh Patel has been appointed as the new Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) effective April 1, 2026. Mr. Bhavik Shah, the current CFO, will transition to a different role within the organization, focusing on plant-related accounting activities, and will continue as Senior Accounts Manager from April 1, 2026.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.